REG - GENinCode PLC - Grant of Share Options & PDMR Dealings

GenincodeAnnouncement

26/03/2025 08:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250326:nRSZ2718Ca&default-theme=true

RNS Number : 2718C  GENinCode PLC  26 March 2025

 

 

26 March 2025

 

 

GENinCode Plc

("GENinCode" or the "Company")

 

Grant of Share Options & PDMR Dealings

 

 

GENinCode Plc (AIM: GENI), the genetics company focused on the prevention of
cardiovascular disease and ovarian cancer, announces that on 21 March 2025 the
Company approved the grant of options over an aggregate of 14,028,305 new
ordinary shares of 1 pence each in the Company ('Ordinary Shares') under the
2021 Share Option Plan ('2021 Share Option Plan') to certain directors and
employees of the Company (the "New Options"), representing 4.89% per cent.
of the Company's existing issued share capital.

 

Terms of the New Options

 

The Company adopted the 2021 Share Option Plan to enable it to retain and
incentivise staff and to reward them for the achievement of its longer-term
objectives. 14,028,305 New Options will be issued at an exercise price of 3.7
pence per share which are exercisable on the second anniversary of the date of
grant. There are no other vesting criteria for the New Options which have a
10-year term.

 

Details of resultant holdings

 

Following the New Options grant and the Option Surrender, details of Options
held by Directors, PDMRs and other employees of the Company, are as follows:

 

 Director's name  Position                  Number of New Options granted at 3.7 pence  Aggregate number of options post grant      Current total beneficial holding of Ordinary Shares           Current holding as a % of Issued share capital
 Matthew Walls     CEO                                   2,431,082                                   5,254,832                                 12,235,473                                         4.26%
 Paul Foulger      CFO                                   2,216,062                                   4,790,062                                       1,273,587                                    0.44%
 Jordi Puig        COO                                       1,462,524                                   3,161,274                             14,737,636                                         5.14%
 William Rhodes   Non-Executive Chair                        554,016                                     1,197,516                                              -                                 0.0%
 Huon Gray        Non-Executive Director                     387,423                                     837,423                                     905,405                                      0.32%
 Felix Frueh      Non-Executive Director                     387,423                                     837,423                                     100,000                                      0.03%
 Sergio Olivero   Non-Executive Director    172,188                                     172,188                                     7,417,243                                                     2.59%
 Other Employees                                         6,417,587                                   16,912,905

                                                                                                                                    N/A                                                           N/A
 Total:                                     12,640,526                                  32,991,435                                  36,669,344                                                    12.78%

 

 

Following the grant of the New Options, there are Options over a total of
32,915,560 Ordinary Shares in the Company as at the date of this announcement,
representing approximately 11.47% of the Company's existing issued share
capital.

 

For more information visit www.genincode.com (http://www.genincode.com)

Enquiries:

 

 GENinCode Plc                      www.genincode.com (http://www.genincode.com) or via Walbrook PR
 Matthew Walls, CEO
 Paul Foulger, CFO

 Cavendish Capital Markets Limited  Tel: +44 (0)20 7397 8900
 Giles Balleny /Dan Hodkinson (Corporate Finance)

 Dale Bellis / Michael Johnson (Sales)

 Nigel Birks (Life Sciences Specialist Sales)

 Ondraya Swanson (Corporate Broking)

 Walbrook PR Limited                                                  Tel: 020 7933 8780 or genincode@walbrookpr.com

 Anna Dunphy / Paul McManus / Louis Ashe-Jepson

 

About GENinCode:

GENinCode Plc is a UK based company specialising in genetic risk assessment of
cardiovascular disease. Cardiovascular disease is the leading cause of death
and disability worldwide.

 

GENinCode operates business units in the UK, Europe through GENinCode S.L.U,
and in the United States through GENinCode U.S. Inc.

 

GENinCode predictive technology provides patients and physicians with globally
leading preventative care and treatment strategies. GENinCode CE marked
invitro-diagnostic molecular tests combine clinical algorithms and
bioinformatics to provide advanced patient risk assessment to predict
cardiovascular disease.

 

 

The notification set out below is provided in accordance with the requirements
of MAR.

 

                           Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No.
                           596/2014
 1                                               Details of the person discharging managerial responsibilities/person closely
                                                 associated
 a.  Name                                                              1.     Matthew Walls

                                                                       2.     Paul Foulger

                                                                       3.     Jordi Puig

                                                                       4.     William Rhodes

                                                                       5.     Huon Gray

                                                                       6.     Felix Frueh

                                                                       7.     Sergio Olivero

 2   Reason for notification
 a.  Position/Status                                                   1.     Chief Executive Officer

                                                                       2.     Chief Financial Officer

                                                                       3.     Chief Operating Officer

                                                                       4.     Non-Executive Chair

                                                                       5.     Non-Executive Director

                                                                       6.     Non-Executive Director

                                                                       7.     Non-Executive Director

 b.  Initial notification/                                             Initial Notification

     Amendment
 3                                               Details of the issuer, emission allowance market participant, auction
                                                 platform, auctioneer or auction monitor
 a.  Name                                                              GENinCode Plc
 b.  LEI                                                               213800UX6TE7K65O2892
 4                                               Details of the transaction(s): section to be repeated for (i) each type of
                                                 instrument; (ii) each type of transaction; (iii) each date; and (iv) each
                                                 place where transactions have been conducted
 a.  Description of the financial instrument, type of instrument       Options over Ordinary Shares of 1p each

Identification Code

                                                                       N/A
 b.  Nature of the transaction                                         Grant of options under the 2021 Share Option Plan with time vesting conditions
                                                                       attached
 c.  Price(s) and volume(s)                                                                            Exercise Price(s)               Volume(s)
                                                 1.                    3.7 pence                       2,431,082

     2.                                                                3.7 pence                       2,216,062
                                                 3.                    3.7 pence                       1,462,524
                                                 4.                    3.7 pence                       554,016
                                                 5.                    3.7 pence                       387,423
                                                 6.                    3.7 pence                       387,423
                                                 7.                    3.7 pence                       172,188

 d.  Aggregated information

     - Aggregated Volume                                               See above

     - Price
 e.  Date of the transaction                                           21 March 2025
 f.  Place of the transaction                                          Outside a trading venue

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHUNOBRVSUOURR